Hey RandAIThor1,
Take a look at the previous royalty deal. It is a pretty sweet deal. Can read comments on it here:
https://hotcopper.com.au/threads/ann-complementary-royalty-funding-for-mt-carbine-development.7033675/
And they have an option for another $10m so I would expect IF capital is needed they would go for the next $10m before a CR.
$6mil in the bank at end of March Quarter. Another $3.6m from government grant the other day. I expect that will be enough to cover them until the open pit profits roll in. Unlike G6M which recently stated it will be months before they ship concentrate EQR gets paid 95% at the mine gate with the 5% sorted post tests at the other end. This should mean once the x10 grade ore starts flowing money should be pretty much straight after I believe.
As Scott said, It would surprise if there was a CR any time soon. If they HAD to I imagine it would be sub $5mil and filled before we even hear about it.
- Forums
- ASX - By Stock
- EQR
- Ann: Webinar - Mt Carbine Tungsten Project Update
Ann: Webinar - Mt Carbine Tungsten Project Update, page-38
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EQR (ASX) to my watchlist
|
|||||
Last
4.4¢ |
Change
0.001(2.33%) |
Mkt cap ! $96.47M |
Open | High | Low | Value | Volume |
4.3¢ | 4.4¢ | 4.2¢ | $11.63K | 270.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 87577 | 4.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.4¢ | 703937 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 87577 | 0.043 |
1 | 250000 | 0.039 |
2 | 21500 | 0.037 |
1 | 28570 | 0.035 |
1 | 31249 | 0.032 |
Price($) | Vol. | No. |
---|---|---|
0.044 | 703937 | 2 |
0.045 | 80000 | 2 |
0.046 | 202000 | 1 |
0.047 | 81088 | 2 |
0.049 | 249998 | 1 |
Last trade - 14.27pm 09/08/2024 (20 minute delay) ? |
Featured News
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
EQR (ASX) Chart |